IRABGLU® 370 MBq/ml solution for injection, 1 vial containing 10 ml AEMPS REGISTRATION No.: 82947 – NATIONAL CODE: 721012 For injection

Fludeoxyglucose (FDG) is the most widely-used radiopharmaceutical in molecular imaging diagnosis, more specifically in PET, being used in more than 90% of all explorations. Its clinical indications of use range from oncology, cardiology and neurology to infectious diseases and inflammatory disorders.

In oncological diagnoses, FDG PET is used to visualize the increase in glucose uptake in organs and tissues. Cancer cells consume more glucose than healthy cells, and it is thereby possible to identify diseased zones. Some of the most common indications are for the detection of tumours of unknown origin, liver or bone metastases, lung cancer, breast cancer, head and neck cancer, colorectal cancer, lymphomas, etc.

In cardiology, FDG PET is used to visualize viable myocardium tissue that takes up glucose but is hypoperfused. When conventional imaging techniques prove inconclusive, FDG PET permits the evaluation of myocardial viability in patients with severe ventricular failure who are candidates for revascularization.

In Neurology, FDG PET is used to study interictal glucose hypometabolism, which is of interest in different diseases such as epilepsy. In the diagnosis of infectious or inflammatory disorders, the objective is to identify tissues or structures with an anomalous presence of activated leukocytes.


18F-beta-amyloid is a radiopharmaceutical compound indicated in imaging diagnostic procedures in neurology. More specifically, it is used to obtain PET images of the density of β-amyloid neuritic plaque in the brain of adult patients with cognitive impairment.

Beta-amyloid plaques are occasional deposits found in the brain of patients with memory problems secondary to dementia in Alzheimer's disease, Lewy body dementia and Parkinson's disease. They are also found in the brain of some elderly people without symptoms.

A negative PET scan using 18F-beta-amyloid tracer indicates the absence or a low density of β-amyloid plaques, which rules out a diagnosis of Alzheimer's disease.


Fluorodopa is a radiopharmaceutical compound generally used in imaging diagnostic procedures in neurology and oncology. The use of PET with [18F]-FDOPA is indicated for detecting a loss of functional dopaminergic nerve endings in the striate nucleus. It can be used as an adjunct in the differential diagnosis of Parkinson's disease and essential or primary tremor and also in the diagnosis of multiple system atrophy and Progressive supranuclear palsy.

In oncological practice, [18F]-FDOPA PET permits the functional study of diseases, organs and tissues with the diagnostic objective of evidencing an increase in intracellular transport and in decarboxylation of the amino acid dihydroxyphenylalanine (DOPA). More particularly, some of the most common indications are the diagnosis of cerebral and neuroendocrine tumours.